Industry: Health care Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A French biotechnology company established in 2023, headquartered in Toulouse, focuses on the use of artificial intelligence combined with genomics to promote precision medical treatment of tumors. The platform developed by the company can analyze the instability of tumor genome, predict patients' response to different treatments, and provide reference for patients' stratification and treatment selection for pharmaceutical companies and doctors based on patented biomarkers. At present, the concept verification has been completed in smooth muscle sarcoma, and it has been extended to a variety of cancer research.
Platform function application:
1. Analysis of tumor genome instability.
Using the whole genome, exons or RNA sequencing data, the genomic instability level of tumor samples was calculated, and the tumors were divided into different risk levels by patent indicators, which provided the basis for clinical decision-making.
2. Patient treatment assistance
Predict the potential response of patients to chemotherapy, DNA damage response inhibitors and immunotherapy.
3. Drug research and development support
It can provide data analysis services for pharmaceutical companies for research and development, assist the development of new drugs, and can be used for the verification of new drug targets, the formulation of clinical strategies and the establishment of curative effect prediction models.
4. Expand the application of multiple cancers.
The concept verification has been completed in smooth muscle sarcoma, and it is expanding to breast cancer, ovarian cancer, lung cancer, gastric cancer and other cancers.
Cooperation mode:
Seek partners who need artificial intelligence tumor gene analysis services in pharmaceutical enterprises, medical and research institutions.